BioAtla’s (BCAB) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of BioAtla (NASDAQ:BCAB) in a report published on Monday,Benzinga reports. HC Wainwright also issued estimates for BioAtla’s FY2029 earnings at ($0.93) EPS.

BioAtla Stock Performance

BCAB stock opened at $0.34 on Monday. BioAtla has a fifty-two week low of $0.24 and a fifty-two week high of $4.02. The firm has a market cap of $16.41 million, a PE ratio of -0.20 and a beta of 1.19. The firm has a fifty day moving average price of $0.40 and a 200 day moving average price of $1.10.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. On average, equities analysts predict that BioAtla will post -1.46 EPS for the current year.

Institutional Trading of BioAtla

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Magnus Financial Group LLC bought a new position in BioAtla during the fourth quarter valued at $28,000. Two Sigma Investments LP boosted its stake in shares of BioAtla by 84.0% during the fourth quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock valued at $80,000 after purchasing an additional 61,725 shares during the period. Jane Street Group LLC boosted its stake in shares of BioAtla by 204.1% during the fourth quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock valued at $88,000 after purchasing an additional 100,204 shares during the period. XTX Topco Ltd grew its holdings in shares of BioAtla by 7.2% in the third quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock worth $273,000 after purchasing an additional 10,384 shares during the last quarter. Finally, Norges Bank bought a new stake in BioAtla during the 4th quarter valued at about $230,000. Hedge funds and other institutional investors own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.